Replies to post #96196 on Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

That combination has made prostate cancer an enticing target for drug developers and in particular those working on cancer immunotherapies, but both PD-1 and PD-L1 checkpoint inhibitors have largely failed as monotherapies.

The hope now is that combinations could unlock the potential of cancer immunotherapy in this form of cancer, by disrupting the tumour and allowing immune cells to mobilise and penetrate the tumour microenvironment.

I believe ADXS_PSA can help increase the efficacy of Pembro. We should know more on Monday.